Cardiac Resynchronization Therapy (CRT): Benefits, Eligibility, and Outcomes

Cardiac Resynchronization Therapy (CRT) is a device-based treatment for selected people with heart failure that improves the timing of ventricular contractions. This article explains how CRT works, which patients may be eligible, the evidence on outcomes, potential risks, and typical follow-up after implantation.

How Cardiac Resynchronization Therapy (CRT) works

Cardiac Resynchronization Therapy uses leads placed in the right atrium, right ventricle, and a coronary vein on the left ventricular surface to deliver synchronized electrical impulses. By restoring coordinated contraction between the left and right ventricles (biventricular pacing), CRT can improve cardiac output, reduce mitral regurgitation in some cases, and relieve symptoms of heart failure caused by ventricular dyssynchrony.

Who may be eligible for CRT

Eligibility criteria are based on symptoms, left ventricular function, and ECG findings. Typical considerations include:

• Symptomatic heart failure (often New York Heart Association class II–IV despite guideline-directed medical therapy).
• Reduced left ventricular ejection fraction (commonly ≤35%).
• Prolonged QRS duration on electrocardiogram, especially with left bundle branch block (LBBB) morphology.
• Ongoing symptoms despite optimized medication and management of reversible causes.

Professional guideline panels such as the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC) provide recommendation frameworks for patient selection. Individual assessment by a cardiology specialist is required to determine suitability for CRT.

Evidence, expected benefits, and outcomes

Randomized trials and observational studies have evaluated CRT in appropriate populations. Major trials reported improvements in symptoms, exercise capacity, quality of life, reductions in heart-failure hospitalizations, and in some studies, reduced mortality for selected patients. Benefits are most pronounced in patients with LBBB and wider QRS durations. Key concepts from the evidence base include response variability (not all patients derive the same benefit) and improved outcomes when CRT is combined with optimal medical therapy.

Device types and implantation procedure

Types of CRT devices

Two general device categories are used: CRT-P (biventricular pacemaker) and CRT-D (biventricular pacemaker combined with an implantable cardioverter-defibrillator). The choice depends on individual arrhythmic risk assessment and guideline recommendations.

Implantation process

Implantation is typically performed in a cardiac catheterization laboratory or electrophysiology suite under local anesthesia and light sedation. Venous access is used to position leads in the right atrium, right ventricle, and a coronary sinus branch over the left ventricle. Fluoroscopy and electrical testing guide lead placement. Procedure duration and complexity vary depending on venous anatomy and lead positioning needs.

Risks and possible complications

Complications occur but are uncommon. They can include:

• Infection at the device pocket or systemic infection.
• Lead dislodgement or malfunction requiring revision.
• Pneumothorax or bleeding related to venous access.
• Failure to respond clinically (nonresponder rate varies).
• Rare procedural risks such as coronary sinus injury or cardiac perforation.

Regulatory bodies, including national health authorities and device regulators, monitor device safety and provide guidance on indications and postmarket surveillance.

Follow-up, programming, and long-term care

Regular follow-up is required after CRT implantation. Follow-up visits assess wound healing, lead function, device battery status, and optimization of pacing settings. Remote monitoring technologies are commonly used to detect arrhythmias, device issues, or heart-failure events between clinic visits. Continued guideline-directed medical therapy for heart failure remains important alongside device therapy.

For more patient-focused information from a major cardiovascular organization, see the American Heart Association overview on cardiac resynchronization therapy: AHA: Cardiac Resynchronization Therapy (CRT).

Decision-making and guidelines

Clinical decisions about CRT are based on published guideline recommendations, clinical trial evidence, and individual patient factors such as comorbidities, life expectancy, and goals of care. Multidisciplinary evaluation by heart failure specialists and electrophysiologists improves selection, implantation planning, and post-procedural management.

Common clinical terms related to CRT

• Biventricular pacing — simultaneous stimulation of both ventricles.
• Left ventricular ejection fraction (LVEF) — a measure of pump function used in eligibility criteria.
• QRS duration and morphology — ECG parameters that predict response.
• CRT-P vs CRT-D — pacemaker alone versus combined pacemaker-defibrillator device.

Conclusion

Cardiac Resynchronization Therapy (CRT) is an established treatment option for appropriately selected people with heart failure and evidence of electrical dyssynchrony. When used according to guideline-based criteria and combined with comprehensive heart-failure care, CRT can improve symptoms, reduce hospitalizations, and enhance quality of life for many patients.

Frequently asked questions

What is Cardiac Resynchronization Therapy (CRT) and how does it differ from a standard pacemaker?

CRT coordinates the timing of left and right ventricular contractions by pacing both ventricles, whereas a standard pacemaker typically paces only one chamber or focuses on atrioventricular timing. CRT addresses ventricular dyssynchrony associated with some forms of heart failure.

Who is most likely to benefit from CRT?

Patients with symptomatic heart failure, reduced LVEF (commonly ≤35%), and a prolonged QRS duration—especially with left bundle branch block—are most likely to benefit. Individual clinical assessment is required.

What are the main risks after CRT implantation?

Risks include infection, lead problems, bleeding, and the possibility of nonresponse. Serious complications are uncommon but possible; device surveillance and follow-up care help manage these risks.

How long does a CRT device last and what follow-up is needed?

Battery life varies by device use and settings but is typically several years. Regular follow-up visits and remote monitoring checks are used to assess battery status, lead integrity, and clinical response.

Are there clinical guidelines and regulatory oversight for CRT?

Yes. Major professional societies such as the ACC, AHA, and ESC publish guideline recommendations, and medical device regulators oversee approval and postmarket safety monitoring.

Note: This article is informational and does not replace clinical judgment or individualized medical evaluation by qualified healthcare professionals.